Details of Disease

General Information of Disease (ID: DIS4W83X)

• Disease Name: Minimally invasive lung adenocarcinoma
• Synonyms: bronchiolo-alveolar adenocarcinoma; bronchioloalveolar lung adenocarcinoma; bronchioloalveolar adenocarcinoma of lung; bronchioalveolar adenocarcinoma of lung; carcinoma, bronchioloalveolar, malignant; bronchiolo-alveolar lung carcinoma; bronchioloalveolar adenocarcinoma of the lung; bronchioloalveolar carcinoma; bronchioalveolar adenocarcinoma of the lung; bac; bronchioalveolar lung carcinoma; bronchiolo-alveolar carcinoma of lung; bronchiolo-alveolar carcinoma of the lung; minimally invasive lung adenocarcinoma
• Definition: A solitary adenocarcinoma arising from the lung measuring 3 cm or less. It is characterized by a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. It is usually a non-mucinous adenocarcinoma, but rarely may be mucinous.
• Disease Hierarchy:
  DISD51WR: Lung adenocarcinoma
  DIS4W83X: Minimally invasive lung adenocarcinoma
• Disease Identifiers:
  MONDO ID: MONDO_0004991
  MESH ID: D002282
  UMLS CUI: C0007120
  MedGen ID: 2871
  HPO ID: HP:0006519
  SNOMED CT ID: 112677002

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Bortezomib	DMNO38U	Approved	Small molecular drug	[1]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 9 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ASPH	TT2KHP7	Limited	Genetic Variation	[2]
CLDN18	TT6PKBX	Limited	Altered Expression	[3]
DYRK2	TT84OS6	Limited	Altered Expression	[4]
EML4	TT92GY4	Limited	Biomarker	[5]
IL31	TT1RJXK	Limited	Altered Expression	[6]
MUC17	TTVO0JU	Limited	Altered Expression	[7]
SLC38A1	TT1YE9Z	moderate	Altered Expression	[8]
TMBIM6	TT7QSMG	moderate	Altered Expression	[9]
KRAS	TTM8FR7	Strong	Biomarker	[10]

This Disease Is Related to 2 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC26A1	DTJ785O	moderate	Altered Expression	[8]
SLC2A10	DT3BI6S	Strong	Altered Expression	[11]

This Disease Is Related to 20 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
EMX2	OT0V8OYK	Limited	Biomarker	[12]
HYAL2	OTTVINXW	Limited	Biomarker	[13]
LOXL1	OTA0NEJU	Limited	Biomarker	[14]
MDH2	OT7364GY	Limited	Altered Expression	[15]
MUC3A	OTI4XUDY	Limited	Altered Expression	[7]
MUC6	OTPVL723	Limited	Altered Expression	[16]
NKX2-1	OTCMEJTA	Limited	Genetic Variation	[17]
PRKRA	OTUTVZZU	Limited	Altered Expression	[18]
RBBP6	OTTVG4HU	Limited	Altered Expression	[18]
RDX	OTNSYUN6	Limited	Altered Expression	[19]
S100A2	OTTGHJ1H	Limited	Biomarker	[20]
SIX3	OTP5E3VU	Disputed	Altered Expression	[21]
ACIN1	OTK81F92	moderate	Posttranslational Modification	[22]
OCIAD2	OTSWB4SZ	moderate	Altered Expression	[23]
COL4A5	OTHG60RE	Strong	Altered Expression	[11]
DCUN1D1	OT8UJLZU	Strong	Altered Expression	[24]
DMP1	OTBWBWW7	Strong	Altered Expression	[25]
GPX7	OTINT9Z4	Strong	Biomarker	[26]
NAPSA	OT6F8IAL	Strong	Biomarker	[27]
LIPH	OTRGYLKL	Definitive	Altered Expression	[28]

References

• [1] Bortezomib FDA Label
• [2] Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas.J Pathol. 2007 Jul;212(3):287-94. doi: 10.1002/path.2165.
• [3] Global gene expression differentiating pure bronchioloalveolar carcinoma from adenocarcinoma with bronchioloalveolar carcinoma features.Eur J Cardiothorac Surg. 2013 Apr;43(4):765-71. doi: 10.1093/ejcts/ezs427. Epub 2012 Aug 3.
• [4] Expression of dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 2 (DYRK2) can be a favorable prognostic marker in pulmonary adenocarcinoma.J Thorac Cardiovasc Surg. 2009 Dec;138(6):1303-8. doi: 10.1016/j.jtcvs.2009.08.003. Epub 2009 Oct 9.
• [5] A case of synchronous bilateral lung cancers: EML4-ALK positive adenocarcinoma in the right lung and adenocarcinoma in situ (the former bronchioloalveolar carcinoma) in the left lung.BMC Pulm Med. 2013 Apr 25;13:25. doi: 10.1186/1471-2466-13-25.
• [6] IL-33/IL-31 axis: a new pathological mechanisms for EGFR tyrosine kinase inhibitors-associated skin toxicity.J Cell Biochem. 2013 Dec;114(12):2673-6. doi: 10.1002/jcb.24614.
• [7] Mucinous bronchioloalveolar carcinomas display a specific pattern of mucin gene expression among primary lung adenocarcinomas.Hum Pathol. 2001 Mar;32(3):274-81. doi: 10.1053/hupa.2001.22752.
• [8] GM3 synthase gene is a novel biomarker for histological classification and drug sensitivity against epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.Cancer Sci. 2007 Oct;98(10):1625-32. doi: 10.1111/j.1349-7006.2007.00578.x. Epub 2007 Aug 16.
• [9] Expression of the Bax inhibitor-1 gene in pulmonary adenocarcinoma.Cancer. 2006 Feb 1;106(3):648-53. doi: 10.1002/cncr.21639.
• [10] Kras, Egfr, and Tp53 Mutations in B6C3F1/N Mouse and F344/NTac Rat Alveolar/Bronchiolar Carcinomas Resulting from Chronic Inhalation Exposure to Cobalt Metal.Toxicol Pathol. 2015 Aug;43(6):872-82. doi: 10.1177/0192623315581192. Epub 2015 Jun 9.
• [11] Elucidating Genomic Characteristics of Lung Cancer Progression from In Situ to Invasive Adenocarcinoma.Sci Rep. 2016 Aug 22;6:31628. doi: 10.1038/srep31628.
• [12] Downregulation of EMX2 is associated with clinical outcomes in lung adenocarcinoma patients.Clin Lung Cancer. 2011 Jul;12(4):237-44. doi: 10.1016/j.cllc.2011.03.025. Epub 2011 Apr 24.
• [13] Hyaluronidase 2 negatively regulates RON receptor tyrosine kinase and mediates transformation of epithelial cells by jaagsiekte sheep retrovirus.Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4580-5. doi: 10.1073/pnas.0837136100. Epub 2003 Apr 3.
• [14] Lysyl oxidase-like protein localizes to sites of de novo fibrinogenesis in fibrosis and in the early stromal reaction of ductal breast carcinomas.Lab Invest. 1998 Feb;78(2):143-51.
• [15] Overexpression of the -opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis.Anesthesiology. 2012 Apr;116(4):857-67. doi: 10.1097/ALN.0b013e31824babe2.
• [16] Expression of MUC1, MUC2, MUC5AC, and MUC6 in atypical adenomatous hyperplasia, bronchioloalveolar carcinoma, adenocarcinoma with mixed subtypes, and mucinous bronchioloalveolar carcinoma of the lung.Am J Clin Pathol. 2004 May;121(5):644-53. doi: 10.1309/U4WG-E9EB-FJN6-CM8R.
• [17] Genotype-phenotype correlation in Chinese patients with pulmonary mixed type adenocarcinoma: Relationship between histologic subtypes, TITF-1/SP-A expressions and EGFR mutations.Pathol Res Pract. 2014 Mar;210(3):176-81. doi: 10.1016/j.prp.2013.11.013. Epub 2013 Dec 5.
• [18] Overexpression of Dicer in precursor lesions of lung adenocarcinoma.Cancer Res. 2007 Mar 1;67(5):2345-50. doi: 10.1158/0008-5472.CAN-06-3533.
• [19] Altered expression of the ERM proteins in lung adenocarcinoma.Lab Invest. 2000 Nov;80(11):1643-50. doi: 10.1038/labinvest.3780174.
• [20] Establishment of an immortalized cell line from a precancerous lesion of lung adenocarcinoma, and genes highly expressed in the early stages of lung adenocarcinoma development.Cancer Sci. 2005 Oct;96(10):668-75. doi: 10.1111/j.1349-7006.2005.00100.x.
• [21] Down-regulation of SIX3 is associated with clinical outcome in lung adenocarcinoma.PLoS One. 2013 Aug 16;8(8):e71816. doi: 10.1371/journal.pone.0071816. eCollection 2013.
• [22] The ACIN1 gene is hypermethylated in early stage lung adenocarcinoma.J Thorac Oncol. 2006 Feb;1(2):160-7.
• [23] OCIA domain containing 2 is highly expressed in adenocarcinoma mixed subtype with bronchioloalveolar carcinoma component and is associated with better prognosis.Cancer Sci. 2007 Jan;98(1):50-7. doi: 10.1111/j.1349-7006.2006.00346.x.
• [24] SCCRO expression correlates with invasive progression in bronchioloalveolar carcinoma.Ann Thorac Surg. 2004 Nov;78(5):1734-41. doi: 10.1016/j.athoracsur.2004.05.056.
• [25] Dentin matrix protein 1 is expressed in human lung cancer.J Bone Miner Res. 2003 Aug;18(8):1506-12. doi: 10.1359/jbmr.2003.18.8.1506.
• [26] DNA hypermethylation regulates the expression of members of the Mu-class glutathione S-transferases and glutathione peroxidases in Barrett's adenocarcinoma. Gut. 2009 Jan;58(1):5-15. doi: 10.1136/gut.2007.146290. Epub 2008 Jul 29.
• [27] Applications and limitations of immunohistochemical expression of "Napsin-A" in distinguishing lung adenocarcinoma from adenocarcinomas of other organs.Appl Immunohistochem Mol Morphol. 2013 May;21(3):191-5. doi: 10.1097/PAI.0b013e3182612643.
• [28] Lipase member H is a novel secreted protein selectively upregulated in human lung adenocarcinomas and bronchioloalveolar carcinomas.Biochem Biophys Res Commun. 2014 Jan 24;443(4):1141-7. doi: 10.1016/j.bbrc.2013.12.106. Epub 2013 Dec 28.